Literature DB >> 10942371

Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies".

D Grimwade1, A Biondi, M J Mozziconacci, A Hagemeijer, R Berger, M Neat, K Howe, N Dastugue, J Jansen, I Radford-Weiss, F Lo Coco, M Lessard, J M Hernandez, E Delabesse, D Head, V Liso, D Sainty, G Flandrin, E Solomon, F Birg, M Lafage-Pochitaloff.   

Abstract

Acute promyelocytic leukemia (APL) is typified by the t(15;17), generating the PML-RAR alpha fusion and predicting a beneficial response to retinoids. However, a sizeable minority of APL cases lack the classic t(15;17), prompting the establishment of the European Working Party to further characterize this group. Such cases were referred to a workshop held in Monza, Italy and subjected to morphologic, cytogenetic, and molecular review, yielding 60 evaluable patients. In the majority (42 of 60), molecular analyses revealed underlying PML/RAR alpha rearrangements due to insertions (28 of 42) or more complex mechanisms, including 3-way and simple variant translocations (14 of 42). Metaphase fluorescence in situ hybridization (FISH) demonstrated that insertions most commonly led to formation of the PML-RAR alpha fusion gene on 15q. In 11 of 60 workshop patients, PLZF/RAR alpha rearrangements were identified, including 2 patients lacking the t(11;17)(q23;q21). In one case with a normal karyotype, FISH analysis revealed insertion of RAR alpha into 11q23, and PLZF-RAR alpha was the sole fusion gene formed. Two patients were found to have t(5;17), one with a diffuse nuclear NPM staining pattern and with NPM-RAR alpha and RAR alpha-NPM transcripts detected. In the other with an unbalanced der(5)t(5;17)(q13;q21) and a nucleolar NPM localization pattern, an NPM/RAR alpha rearrangement was excluded, and FISH revealed deletion of one RAR alpha allele. In the remaining 5 workshop patients, no evidence was found for a rearrangement of RAR alpha, indicating that in rare instances, alternative mechanisms could mediate the differentiation block that typifies this disease. This study highlights the importance of combining morphologic, cytogenetic, and molecular analyses for optimal management of APL patients and better understanding of the pathogenesis of the disease. (Blood. 2000;96:1297-1308)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942371

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  68 in total

1.  No evidence for PML-RARa bcr1 fusion gene in colorectal cancer.

Authors:  Marta Herreros-Villanueva
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

2.  PML-retinoic acid receptor alpha inhibits PML IV enhancement of PU.1-induced C/EBPepsilon expression in myeloid differentiation.

Authors:  Hitoshi Yoshida; Hitoshi Ichikawa; Yusuke Tagata; Takuo Katsumoto; Kazunori Ohnishi; Yukihiro Akao; Tomoki Naoe; Pier Paolo Pandolfi; Issay Kitabayashi
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

3.  The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.

Authors:  Jie Zhao; Jian-Wei Liang; Hui-Liang Xue; Shu-Hong Shen; Jing Chen; Yan-Jing Tang; Li-Sha Yu; Huan-Huan Liang; Long-Jun Gu; Jing-Yan Tang; Ben-Shang Li
Journal:  Leukemia       Date:  2018-12-21       Impact factor: 11.528

4.  Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions.

Authors:  Lijun Wen; Yang Xu; Li Yao; Nana Wang; Qinrong Wang; Tianhui Liu; Jinlan Pan; Jiannong Cen; Huifeng Zhou; Miao Miao; Yang W Shao; Xiaonan Wang; Xiaoxia Wang; Changgeng Ruan; Depei Wu; Suning Chen
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

5.  Role of arsenic trioxide in acute promyelocytic leukemia.

Authors:  Harry J Iland; John F Seymour
Journal:  Curr Treat Options Oncol       Date:  2013-06

6.  Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion.

Authors:  Kiyoshi Okazuka; Masayoshi Masuko; Yoshinobu Seki; Hitomi Hama; Noriyuki Honma; Tatsuo Furukawa; Ken Toba; Kenji Kishi; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

7.  Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Authors:  José Cervera; Pau Montesinos; Jesús M Hernández-Rivas; María J Calasanz; Anna Aventín; María T Ferro; Elisa Luño; Javier Sánchez; Edo Vellenga; Chelo Rayón; Gustavo Milone; Javier de la Serna; Concha Rivas; José D González; Mar Tormo; Elena Amutio; Marcos González; Salut Brunet; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

8.  Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.

Authors:  Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

Review 9.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

10.  Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastocytosis.

Authors:  Hirokazu Kanegane; Keiko Nomura; Akihiro Abe; Teruhiko Makino; Shin Ishizawa; Tadamichi Shimizu; Tomoki Naoe; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2008-12-04       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.